Our top pick for
Fulgent Genetics, Inc is a diagnostics & research business based in the US. Fulgent Genetics shares (FLGT) are listed on the NASDAQ and all prices are listed in US Dollars. Fulgent Genetics employs 473 staff and has a trailing 12-month revenue of around USD$135.1 million.
|52-week range||USD$6.7 - USD$189.89|
|50-day moving average||USD$104.0388|
|200-day moving average||USD$56.1039|
|Wall St. target price||USD$85|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$2.14|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Fulgent Genetics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Fulgent Genetics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Fulgent Genetics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Fulgent Genetics shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Fulgent Genetics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Fulgent Genetics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Fulgent Genetics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$66.2 million.
The EBITDA is a measure of a Fulgent Genetics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$135.1 million|
|Operating margin TTM||47.25%|
|Gross profit TTM||USD$18.4 million|
|Return on assets TTM||25.87%|
|Return on equity TTM||39.51%|
|Market capitalisation||USD$2.6 billion|
TTM: trailing 12 months
There are currently 4.2 million Fulgent Genetics shares held short by investors – that's known as Fulgent Genetics's "short interest". This figure is 0.8% up from 4.1 million last month.
There are a few different ways that this level of interest in shorting Fulgent Genetics shares can be evaluated.
Fulgent Genetics's "short interest ratio" (SIR) is the quantity of Fulgent Genetics shares currently shorted divided by the average quantity of Fulgent Genetics shares traded daily (recently around 2.5 million). Fulgent Genetics's SIR currently stands at 1.68. In other words for every 100,000 Fulgent Genetics shares traded daily on the market, roughly 1680 shares are currently held short.
However Fulgent Genetics's short interest can also be evaluated against the total number of Fulgent Genetics shares, or, against the total number of tradable Fulgent Genetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fulgent Genetics's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 Fulgent Genetics shares in existence, roughly 170 shares are currently held short) or 0.2898% of the tradable shares (for every 100,000 tradable Fulgent Genetics shares, roughly 290 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Fulgent Genetics.
Find out more about how you can short Fulgent Genetics stock.
We're not expecting Fulgent Genetics to pay a dividend over the next 12 months.
Over the last 12 months, Fulgent Genetics's shares have ranged in value from as little as $6.7 up to $189.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulgent Genetics's is 1.6935. This would suggest that Fulgent Genetics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home Covid-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.